Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

This was the stock's fourth consecutive day of losses.

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

This was the stock's third consecutive day of losses.

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $91.41 which represents a decrease of $-0.47 or -0.51% from the prior close of $91.88. The stock opened at $92.19 and touched a low of ...